United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, August 17th. The stock was sold at an average price of $506.59, for a total transaction of $4,812,605.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $164,359,579.37. The trade was a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Up 1.9%

NASDAQ UTHR opened at $518.27 on Wednesday. The company has a 50-day simple moving average of $534.53 and a two-hundred day simple moving average of $536.74. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The firm has a market cap of $22.23 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the previous year, the business earned $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on UTHR. Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $646.00.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $26,000. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the second quarter valued at approximately $30,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter worth approximately $31,000. Finally, Caitlin John LLC purchased a new position in United Therapeutics in the 2nd quarter worth approximately $37,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.